GLP-1 receptor agonists' cardiorenal effects in chronic kidney disease: systematic review and meta-analysis (summary)

A systematic review and meta-analysis of randomized trials found that GLP-1 receptor agonists in CKD patients, predominantly with type 2 diabetes, were associated with lower rates of major renal and cardiovascular events but were notable for gastrointestinal adverse effects [1].

Study type: Journal Article, Systematic Review, Meta-Analysis (classification: clinical guideline/high-quality systematic review) Published: Renal failure, 2026-12-05 Source: PubMed public abstract

A systematic review and meta-analysis of randomized trials found that GLP-1 receptor agonists in CKD patients, predominantly with type 2 diabetes, were associated with lower rates of major renal and cardiovascular events but were notable for gastrointestinal adverse effects [1].

Why this study matters

Why know this study?

Chronic kidney disease (CKD) patients frequently have comorbid cardiovascular disease and type 2 diabetes mellitus (T2DM); treatment choices involve balancing cardiac and renal risks. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used in diabetes management, but whether they provide cardiorenal protection and their safety in CKD patients have shown mixed reports. This systematic review and meta-analysis pooled randomized controlled trials up to December 2024 to evaluate the cardiac and renal outcomes and adverse events of GLP-1 RAs in CKD patients, to inform clinicians and patients [1].

What the study actually found

Main findings (data reported in the abstract, all quoted from [1]):

• This analysis included 9 randomized trials with a total of 21,717 participants, the vast majority of whom had type 2 diabetes.
• Compared with control, GLP-1 RAs were associated with a lower incidence of major adverse kidney events (MAKE) (RR 0.84; 95% CI 0.76–0.94).
• GLP-1 RAs were also associated with a lower incidence of major adverse cardiovascular events (MACE) (RR 0.84; 95% CI 0.72–0.97).
• All-cause mortality was also lower with GLP-1 RAs (RR 0.83; 95% CI 0.76–0.90).
• For proteinuria (or urine albumin) measures, users had lower albuminuria levels (standardized mean difference SMD -1.22; 95% CI -1.53 to -0.90).
• For safety, GLP-1 RAs were associated with higher gastrointestinal adverse events, including nausea (RR 4.14; 95% CI 2.70–6.33), vomiting (RR 3.05; 95% CI 1.88–4.97), diarrhea (RR 2.65; 95% CI 1.76–3.98) and dyspepsia (RR 3.79; 95% CI 1.02–14.12).

Possible implications for CKD, dialysis, or transplant patients

How to interpret these results?

• Reported associations: This analysis reports statistical associations between GLP-1 RAs and reductions in MAKE, MACE, all-cause mortality, and lower urine protein levels, but these are pooled randomized trial data and should be described as associations rather than direct causation from this analysis alone. All data and conclusions are taken from the systematic review and meta-analysis abstract [1].

• Conclusions with sufficient evidence: The abstract shows a substantial number of trials and participants, with consistent favorable associations across several clinical endpoints; however, declaring "sufficient evidence" usually requires full-text review of individual trials, heterogeneity analyses, subgroup analyses, and long-term safety follow-up—details not available in the abstract—so the abstract alone cannot establish clinical consensus.

• Clinical considerations: The study also reports a marked increase in gastrointestinal adverse effects, which must be weighed against benefits when making treatment decisions and discussed with the treating physician, especially for populations predominantly with T2DM.

Current study limitations

Limitations (particularly important to note for this summary):

• This article is written based on the PubMed public abstract and the full text was not reviewed; therefore detailed methods of individual trials, follow-up duration, baseline kidney function distribution, whether dialysis or transplant patients were included, and other sensitivity and subgroup analyses cannot be examined.
• The abstract states that the majority of participants were T2DM, but does not specify the proportion of non-diabetic CKD; thus generalizability to non-diabetic CKD is limited.
• The abstract cannot fully reveal heterogeneity between trials, differences in specific drugs or dosages, concomitant medications, or long-term safety and rare adverse event information.
• A single systematic review/meta-analysis does not represent medical consensus; clinical decisions should consider the individual patient's overall situation and be discussed with clinicians.

All above limitations are based on the abstract content; the lack of full-text review requires cautious interpretation of conclusions [1].

What remains uncertain

Questions requiring further research:

• Do non-T2DM CKD patients experience the same cardiorenal protective effects?
• What are the benefits and risks of GLP-1 RAs in advanced CKD (e.g., approaching or receiving dialysis) or in kidney transplant recipients?
• The long-term (multi-year) effects of GLP-1 RAs on kidney function trajectory and rare adverse events remain unclear.
• Are there efficacy or safety differences among different GLP-1 RAs, and what are the interaction details with other renal or cardiovascular medications?
• How can clinicians mitigate or manage the increased gastrointestinal adverse events to improve tolerability?

These remain hypotheses or require confirmation and need original trial full texts, long-term follow-up, and studies in specific populations (e.g., non-T2DM, dialysis, or transplant patients).

Questions to discuss with your healthcare team

• Does my CKD stage and presence or absence of type 2 diabetes affect whether GLP-1 RAs are appropriate for me?
• In my case, what are the expected benefits and risks of using GLP-1 RAs?
• If I am taking other glucose-lowering or cardiovascular drugs, are there interactions or precautions with GLP-1 RAs?
• If I start GLP-1 RAs, what monitoring or follow-up is needed (kidney function, cardiovascular checks, gastrointestinal tolerability, etc.)?
• How are gastrointestinal adverse events typically managed clinically? When should medication be stopped or changed?
• Are there safety data specifically for dialysis or kidney transplant patients? (If not, does this affect my medication decision?)

How to read this study (our interpretation)

This section was written by the Beyond CKD editor — a kidney-transplant recipient with a health-management background, not a physician — using only the PubMed abstract. We have not read the full paper, and no clinician has reviewed this text. It is meant to help you understand the numbers, not to advise treatment.

What the study asked

This meta-analysis asks whether GLP-1 receptor agonists (injectables such as semaglutide or dulaglutide) reduce kidney and cardiovascular harm in people with chronic kidney disease, and how large the side-effect burden is. The authors pooled 9 randomised trials with 21,717 participants, almost all of whom also had type 2 diabetes.

How to read the results

A risk ratio of 0.84 means the treated group had major kidney events at about 84% of the control rate — roughly 16% fewer. The 95% confidence interval (0.76–0.94) does not cross 1, so the difference is statistically solid. Heart and stroke events were also about 16% lower (0.72–0.97; the lower bound is close to 1, so this is real but less certain), and deaths from any cause about 17% lower (0.76–0.90). Keep relative and absolute risk apart: if your baseline one-year risk were 10%, a 16% relative reduction takes it to about 8.4%. Gastrointestinal effects are the other side of the coin: nausea about 4 times as common, vomiting 3 times, diarrhoea 2.7 times. Dyspepsia had an RR of 3.79 but a very wide interval (1.02–14.12), which tells you the data were thin.

Limitations

We only had the abstract. It does not say which CKD stages were included, how long people were followed, or whether dialysis patients were eligible. The findings come overwhelmingly from people with diabetes, so they may not transfer to CKD without diabetes. Pooling different drugs and doses hides any differences between individual agents.

What it means for readers and people with kidney disease

If you have both type 2 diabetes and CKD, the evidence that these drugs protect the heart and kidneys is now fairly consistent, and it is a reasonable thing to raise with your nephrologist or diabetes doctor. It does not show the same benefit for people without diabetes or people already on dialysis. The stomach side effects are common and usually managed by very gradual dose increases.

How to check further

Questions for your clinic: Are my kidney function and diabetes similar to the trial participants? If I start one of these drugs, how will we handle nausea? How does it fit with my SGLT2 inhibitor or blood-pressure medication?

Original abstract: PubMed 41644273 (https://pubmed.ncbi.nlm.nih.gov/41644273/). Interpretation last updated 2026-11-06.

References

[1] Wang Y, Feng L, Wang Y, Li B, Liang N, Song X. Cardiorenal protective effects of glucagon-like peptide-1 receptor agonists in chronic kidney disease: a systematic review and meta-analysis.. Renal failure. 2026. DOI: 10.1080/0886022X.2026.2620155. PMID: 41644273.

Medical disclaimer: This article is for general health education and information only. It does not constitute individual medical diagnosis, treatment advice, or a doctor–patient relationship. Medical research is continually updated, and study findings have their own scope and limitations. Every patient's condition, laboratory values, medications and treatment needs differ. Do not stop or adjust medication doses, change your diet or fluid intake, or alter dialysis or transplant treatment based on this article alone. For any medical questions, please consult your nephrologist or another qualified healthcare professional.

Article created: 2026-10-26 | Original study published: 2026-12-05 | Last checked: 2026-10-26 (source metadata has been checked against PubMed)